NEGXF (NexgenRx) EBIT per Share : $0.00 (TTM As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is NexgenRx EBIT per Share?

NexgenRx's EBIT per Share for the three months ended in Sep. 2024 was $0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for NexgenRx's EBIT per Share or its related term are showing as below:

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of NexgenRx was 58.70% per year. The lowest was -51.90% per year. And the median was 20.20% per year.

NEGXF's 3-Year EBIT Growth Rate is not ranked ^*
in the Healthcare Plans industry.
Industry Median: 2.95
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

NexgenRx's EBIT for the three months ended in Sep. 2024 was $0.10 Mil.

NexgenRx EBIT per Share Historical Data

The historical data trend for NexgenRx's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NexgenRx EBIT per Share Chart

NexgenRx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

0.02

NexgenRx Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT per Share	Get a 7-Day Free Trial															-	-	0.01	-	-

NexgenRx EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

NexgenRx's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.206	/	70.531
=	-0.00

NexgenRx's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

	EBIT per Share		(Q: Sep. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	0.099	/	74.615
=	0.00

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00

NexgenRx (OTCPK:NEGXF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

NexgenRx EBIT per Share Related Terms

Thank you for viewing the detailed overview of NexgenRx's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

NexgenRx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Plans » NexgenRx Inc (OTCPK:NEGXF) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

NXG:Canada

Address

191 The West Mall, Suite 905, Toronto, ON, CAN, M9C 5L6

Website

http://www.nexgenrx.com

NexgenRx Inc administers, adjudicates and pays drug, dental and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers using proprietary computer software and provides ancillary services. Some of the products and services of the company are Dental Claims, Prescription Drug Claims and many more.